— Technology Description
Researchers in Prof. Jeffrey Henderson’s laboratory have discovered a drug target and a class of small molecule candidates that could be used to selectively prevent pathogenic enterobacteria from causing diseases such as urinary tract infections (UTIs).
Currently, UTI…
— Disease indication – Tetracycline resistant infections
Drug format – Small molecule (anhydrotetracycline (aTC) or analogs)
Drug class – Combination therapy
Research stage and Preliminary data
Target – Tetracycline destructases (Tet(X), Tet(50), etc)
Background &ndas…
— Background
Frontotemporal Dementia (FTD) is the second most common form of non-Alzheimer’s dementia in the population under 65 years old. FTD represents approximately 20% of all dementias and onset normally appears in the mid to late 50s. Clinically FTD is characterized by a progressive neur…
— Dr. Hiroko Yano and Dr. Albert Kim, and their research teams at the Washington University School of Medicine in St. Louis developed and extensively evaluated a novel therapeutic approach using DNMT inhibitors to treat Huntington’s Disease (HD) and other neurodegenerative disorders. Currently D…
— The monoclonal antibodies developed are agaonistic monoclonal antibodies. These antibodies can help in enhancing the immune system by activating dendritic cell subsets. Furthermore, these antibodies are unique, as they can activate Dendritic cells without the need for cross-linking the receptor.
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
